Academic Background Diffuse Large B Cell Lymphoma (DLBCL) is an aggressive form of B-cell non-Hodgkin lymphoma (B-NHL), accounting for approximately 30% of all non-Hodgkin lymphomas. Although first-line immunochemotherapy (e.g., R-CHOP regimen) has shown efficacy in DLBCL patients, about 30% of patients relapse or become refractory (relapsed/refrac...

CM313 Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma or Marginal Zone Lymphoma: A Multicenter Phase 1 Dose-Escalation and Expansion Trial Academic Background Multiple Myeloma (MM) is a common hematologic malignancy, accounting for approximately one-tenth of all hematologic malignancies. Although the use of immunomodulatory drugs ...

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: A Multicenter, Retrospective Real-World Study Background and Research Motivation Multiple sclerosis (MS) is a chronic, complex, inflammatory, and degenerative demyelinating disease primarily affecting the central nervous system (CNS). It can lead to neurological impairments in ...